Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unres
- PDF / 528,941 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 80 Downloads / 191 Views
ORIGINAL ARTICLE
Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5‑fluorouracil Hiromichi Shirasu1 · Tomoya Yokota1 · Takeshi Kawakami1 · Satoshi Hamauchi1 · Yusuke Onozawa2 · Hirofumi Ogawa3 · Tsuyoshi Onoe3 · Keita Mori4 · Tetsuro Onitsuka5 Received: 26 March 2020 / Accepted: 26 June 2020 © Japan Society of Clinical Oncology 2020
Abstract Background Docetaxel, cisplatin, and 5-fluorouracil (TPF) induction chemotherapy (ICT) is a treatment option for locally advanced unresectable head and neck squamous cell carcinoma (LA-HNSCC). However, patients with advanced age, or renal, cardiac or neurogenic dysfunction are ineligible for ICT-TPF. Methods We retrospectively assessed 24 unresectable LA-HNSCC patients who received paclitaxel, carboplatin and cetuximab (PCE) as ICT at the Shizuoka Cancer Center between April 2013 and October 2018. Results Patient characteristics were as follows: median age, 72 years (range 60–81); 0, 1, and 2 performance status (PS), 1, 15, and 8 patients, respectively, and creatinine clearance ≥ 60 mL/min or
Data Loading...
